How big is Recursion Pharmaceuticals, Inc.?

As of Jun 18, Recursion Pharmaceuticals, Inc. has a market capitalization of 1,967.44 million, with net sales of 59.79 million and a net profit of -574.78 million over the last four quarters. The company reported shareholder's funds of 1,034.78 million and total assets of 1,448.60 million as of Dec 24.

Market Cap: As of Jun 18, Recursion Pharmaceuticals, Inc. has a market capitalization of 1,967.44 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Recursion Pharmaceuticals reported net sales of 59.79 million and a net profit of -574.78 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,034.78 million and total assets of 1,448.60 million.

What does Recursion Pharmaceuticals, Inc. do?

Recursion Pharmaceuticals, Inc. is a small-cap biotechnology company focused on pharmaceuticals, with recent net sales of $15 million and a net loss of $202 million as of March 2025. The company has a market cap of approximately $1.97 billion and does not pay dividends.

Overview:<BR>Recursion Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 15 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -202 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,967.44 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.50 <BR>Return on Equity: -61.54% <BR>Price to Book: 2.11 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Recursion Pharmaceuticals, Inc.?

Is Recursion Pharmaceuticals, Inc. overvalued or undervalued?

As of May 12, 2021, Recursion Pharmaceuticals, Inc. is considered risky and overvalued due to poor financial ratios and significant negative returns, underperforming both its peers and the S&P 500.

As of 12 May 2021, the valuation grade for Recursion Pharmaceuticals, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued, given its significant negative return metrics and poor financial ratios. Key ratios include a Price to Book Value of 2.39, an EV to EBIT of -3.07, and an EV to EBITDA of -3.36, all of which suggest underlying weaknesses in profitability and valuation.<BR><BR>In comparison to peers, Recursion Pharmaceuticals has a notably worse EV to EBITDA ratio than Arcellx, Inc. at -16.81 and Beam Therapeutics, Inc. at -2.08, highlighting its relative underperformance. Additionally, the company's stock has underperformed against the S&P 500, with a 1-year return of -28.65% compared to the index's 17.14%, reinforcing the notion that it is overvalued in the current market context.

Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?

As of October 24, 2025, Recursion Pharmaceuticals, Inc. shows a neutral technical trend with mixed indicators, including mildly bullish weekly and monthly MACD, but bearish daily moving averages, suggesting a cautious approach despite recent outperformance against the S&P 500.

As of 24 October 2025, the technical trend for Recursion Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators influencing this outlook. The weekly MACD is mildly bullish, while the monthly MACD also indicates a mildly bullish trend. However, the daily moving averages are mildly bearish, and the KST shows bearish signals on both weekly and monthly time frames. The Dow Theory supports a mildly bullish stance on both weekly and monthly periods, and the OBV is bullish in both time frames. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 3.07% and 23.77% respectively, while it has underperformed over longer periods, including a -10.65% YTD return compared to the S&P 500's 15.47%. Overall, the mixed signals suggest a cautious approach.